Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome

American Journal of Cardiology

Volumn 90, Issue 5 SUPPL., 2002, Pages 19-26

  Reusch, Jane E B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DISEASE COURSE; DYSLIPIDEMIA; EXERCISE; FIBRINOLYSIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; MITOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0037026740     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02555-9     Document Type: Article

References (41)

1. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458.
2. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
3. Haffner S.M., Mykkanen L., Festa A., Burke J.P., Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation. 101:2000;975-980.
4. Fontbonne A.M., Eschwege E.M. Insulin and cardiovascular disease Paris Prospective Study . Diabetes Care. 14:1991;461-469.
5. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men prospective results from the Quebec Cardiovascular Study . Circulation. 95:1997;69-75.
6. Pyörälä M., Miettinen H., Halonen P., Laakso M., Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men the 22-year follow-up results of the Helsinki Policemen Study . Arterioscler Thromb Vasc Biol. 20:2000;538-544.
7. Pyörälä M., Miettinen H., Laakso M., Pyörälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men the 22-year follow-up results of the Helsinki Policemen Study . Circulation. 98:1998;398-404.
8. Salomaa V., Riley W., Kark J.D., Nardo C., Folsom A.R. Arterial disease/hypertension/angiotensin system non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC study . Circulation. 91:1995;1432-1443.
9. Welborn T.A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 2:1979;154-160.
10. Lempiainen P., Mykkanen L., Pyörälä K., Laakso M., Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 100:1999;123-128.
11. Liao D., Arnett D.K., Tyroler H.A., Riley W.A., Chambless L.E., Szklo M., Heiss G. Arterial stiffness and the development of hypertension the ARIC study . Hypertension. 34:1999;201-206.
12. Reaven G.M., Chen Y.D.I., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense, low-density lipoprotein particles. J Clin Invest. 92:1993;141-146.
13. Murphy K, Salzman A. Rosiglitazone is superior to glyburide in establishing long-term glycemic control in patients with type 2 diabetes [abstract 1827]. Presented at the 82nd Annual Meeting of the American Endocrine Society; June 21-24, 2000; Toronto, Ontario, Canada.
14. Brunzell J., Cohen B., Kreider M., Biswas N., Ratner R., Freed M., Marcovina S. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes. 50:(suppl 2):2001;A141.
15. Hirose H., Kawai T., Yamamoto Y., Taniyama M., Tomita M., Matsubara K., Okazaki Y., Ishii T., Oguma Y., Takei I., Saruta T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 51:2002;314-331.
16. Rosenblatt S., Miskin B., Glazer N.B., Prince M.J., Robertson K.E., Pioglitazone 026 Study Group . The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 12:2001;413-423.
17. Carey D.G., Jenkins A.B., Campbell L.V., Freund J., Chisholm D.J. Abdominal fat and insulin resistance in normal and overweight women direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM . Diabetes. 45:1996;633-638.
18. Kelly I., Han T., Walsh K., Lean M.E.J. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 22:1999;288-293.
19. Akazawa S., Sun F., Ito M., Kawasaki E., Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 23:2000;1067-1071.
20. Arioglu E., Duncan-Morin J., Sebring N., Rother K.I., Gottlieb N., Lieberman J., Herion D., Kleiner D.E., Reynolds J., Premkumar A., Sumner A.E., Hoofnagle J., Reitman M.L., Taylor S.I. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 133:2000;263-274.
21. Carey DG, Galloway G, Dodrell D, Richards J, Jones NP, Zhou B. Rosiglitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots [abstract 271]. Presented at the 36th Annual Meeting of the European Association for the Study on Diabetes; September 17-21, 2000; Jerusalem, Israel.
22. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Cusi K., Mandarino L.J., DeFronzo R.A. Relationship between visceral fat and enhanced peripheral/hepatic insulin sensitivity after pioglitazone in type 2 diabetes. Diabetes. 50:(suppl 2):2001;A126.
23. Dandona P., Aljada A., Mohanty P., Ghamin H., Hamouda W., Assian E., Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects evidence for an anti-inflammatory effect? J Clin Endocinol Metab. 86:2001;3257-3265.
24. Garg R., Kumbkarni Y., Aljada A., Mohanty P., Ghanim H., Hamouda W., Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 36:2000;430-435.
25. Cusi K., Maezono K., Osman A., Pendergrass M., Patti M.E., Pratipanawatr T., DeFronzo R.A., Kahn C.R., Mandarino L.J. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 105:2000;311-320.
26. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction implications for the syndrome of insulin resistance . J Clin Invest. 97:1996;2601-2610.
27. Montagnani M., Golovchenko I., Kim I., Koh G.Y., Goalstone M.L., Mundhekar A.N., Johansen M., Kucik D.F., Quon M.J., Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 277:2002;1794-1799.
28. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1992;1076-1083.
29. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 27:1996;567-574.
30. Avena R., Mitchell M.E., Nylen E.S., Curry K.M., Sidawy A.N. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg. 28:1998;1024-1032.
31. Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 37:2001;1344-1350.
32. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1) evidence of a potent anti-inflammatory effect . Diabetes. 50:(suppl 2):2001;A68.
33. Brandenburg S.L., Reusch J.E., Felder K.K., Nelson-Wong E., Lindenfeld J., Manco-Johnson M., Regensteiner J.G. Impaired fibrinolysis in premenopausal women and age-matched men with type 2 diabetes mellitus a pilot study . J Invest Med. 50:2002;110-115.
34. Meigs J.B., Mittleman M.A., Nathan D.M., Tofler G.H., Singer D.E., Murphy-Sheehy P.M., Lipinska I., D'Agostino R.B., Wilson P.W.F. Hyperinsulinemia, hyperglycemia, and impaired hemostasis the Framingham Offspring Study . JAMA. 283:2000;221-228.
35. Freed M., Fuell D., Menci L., Heise M., Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 43:(suppl 1):2000;A267.
36. Fonseca V.A., Reynolds T., Hemphill D., Randolph C., Wall J., Valiquet T.R., Graveline J., Fink L.M. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 12:1998;181-186.
37. Wei M., Gibbons L.W., Kampert J.B., Nichaman M.Z., Blair S.N. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med. 132:2000;605-611.
38. Wei M., Kampert J.B., Barlow C.E., Nichaman M.Z., Gibbons L.W., Paffenbarger R.S. Jr, Blair S.N. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA. 282:1999;1547-1553.
39. Brandenburg S.L., Reusch J.E.B., Bauer T.A., Jeffers B.W., Hiatt W.R., Regensteiner J.G. Effects of exercise training on oxygen uptake kinetic responses in women with type 2 diabetes. Diabetes Care. 22:1999;1640-1646.
40. Regensteiner J.G., Bauer T.A., Reusch J.E.B., Brandenburg S.L., Sippel J.M., Vogelsong A.M., Smith S., Wolfel E.E., Eckel R.H., Hiatt W.R. Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. J Appl Physiol. 85:1998;310-317.
41. Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.